Upstream Bio (UPB) Change in Receivables (2023 - 2026)
Upstream Bio (UPB) recorded quarterly Change in Receivables of $366000.0 in Q1 2026, up 2540.0% quarter-over-quarter from -$15000.0 in Q4 2025, and up 878.72% on a YoY basis from $37395.7 in Q1 2025.
Upstream Bio (UPB) Change in Receivables (2023 - 2026) Analysis & Trends
Upstream Bio's Change in Receivables history runs 4 years deep, the most recent figure standing at $366000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 878.72% year-over-year to $366000.0; the TTM figure through Mar 2026 stood at $468000.0 (up 372.09% YoY), while the FY2025 annual figure was $55000.0, down 89.32% from the prior year.
- Change in Receivables was $366000.0 for Q1 2026 at Upstream Bio, up from -$15000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $640000.0 in Q1 2024 to a low of -$254000.0 in Q3 2025.
- Historically, Change in Receivables has averaged $76900.0 across 4 years, with a median of -$4500.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables plunged 361.86% in 2025, then soared 878.72% in 2026.
- A 4-year view of Change in Receivables shows it stood at -$167000.0 in 2023, then jumped by 103.59% to $6000.0 in 2024, then sank by 350.0% to -$15000.0 in 2025, then jumped by 2540.0% to $366000.0 in 2026.
- The last three Change in Receivables figures came in at $366000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$254000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | 366,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 366,000.00 |
| Mar 31, 2026 | 366,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Mar 31, 2024 | 640,000.00 |
| Mar 31, 2024 | 640,000.00 |
| Dec 31, 2023 | -167,000.00 |
| Dec 31, 2023 | -167,000.00 |